Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry

NCT06992076 · tracked via the Priya Life Science China tracker

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Phase

Observational

Started

2026-02-15

Last updated

2026-04-29

Condition(s) studied

Hemophilia

Investigational drug(s) / intervention(s)

Marstacimab →

Marstacimab: the first visit (V1) is scheduled on the day of the first administration of marstacimab. The recommended dosing frequency for the patient should follow the instructions provided, which are as follows: On Day 1, administer 300 mg subcutaneously (divided into two injections, each 150 mg) (loading dose); starting from Day 8, administer 150 mg subcutaneously once a week. Record the patient's prescription recommendations, actual treatment records (administration time, dosage, frequency), and adherence rates. Visit 2 (V2) and visit 3 (V3) are defined as 30 days (±7 days) and 180 days (±30 days) after the initiation of marstacimab treatment, respectively.

Study summary

Research Title：Adult and adolescent hemophilia patients treated with Marstacimab: a patient Experience Registry (AMBER) Protocol Number：94250855 Protocol Version Number：version 0.3 Date：15-November-2024 Leading site：Institution of Hematology \& Blood Diseases Hospital, Chinese Academy of Medical Sciences Active Pharmaceutical Ingredient：a human IgG1 monoclonal antibody that targets the tissue factor pathway inhibitor (TFPI) Drug Name Generic name: marstacimab-hncq Purpose of the Study Primary Objectives:To quantify patient preferences for subcutaneous versus intravenous (IV) injection using the Marstacimab-Patient Preference Questionnaire (M-PPQ) after 1 month of marstacimab for routine prophylaxis treatment.

To assess the treatment burden using the Hemophilia Treatment Experience Measure (Hemo-TEM) in hemophilia patients after 6 months of marstacimab for routine prophylaxis treatment.

Exploratory Objectives:

To evaluate the annualized bleeding rate (ABR) of different types of bleeds after 6 months of subcutaneous marstacimab injections in hemophilia patients.

To assess changes in joint status scores between baseline and the final visit after 6 months of subcutaneous marstacimab injections in hemophilia patients, using the Hemophilia Early Arthropathy Detection with Ultrasound in China (HEAD-US-C).

To evaluate patient preferences regarding treatment experience via M-PPQ after 6 months

Eligibility

Sex

ALL

Min age

12 Years

Max age

—

Healthy volunteers

Inclusion Criteria: \- Participants with a diagnosis of hemophilia A or hemophilia B eligible to receive prophylaxis. Clinical physicians prescribe marstacimab for routine prophylaxis treatment of hemophilia patients based on the actual conditions of the patients and in accordance with the approved indications of marstacimab. Adolescent patients(12 to less than 18 years) and adult (18 years and older) patients. Signed consent obtained before the study, participant or legally authorized representative, or participant's caregiver capable of giving signed informed consent. Exclusion Criteria: \- Those who are unable to complete at least one month follow-up based on the investigator's judgment. Severe impairment of speech, vision, memory or cognition that affects communication and ability to complete questionnaires and follow-up visits. Women of childbearing age who plan to become pregnant within the next 2 months, as well as women who are pregnant or breastfeeding. Patients are participating in other clinical trials. There are other conditions that the investigator deems unsuitable for participation in this study.

Primary outcome measure(s)

patient preferences for subcutaneous — after 1 month of marstacimab treatment
To quantify patient preferences for subcutaneous versus intravenous (IV) injection using the Marstacimab-Patient Preference Questionnaire (M-PPQ) after 1 month of marstacimab for routine prophylaxis treatment.
To assess the treatment burden — after 6 month of marstacimab treatment
To assess the treatment burden using the Hemophilia Treatment Experience Measure (Hemo-TEM) in hemophilia patients after 6 months of marstacimab for routine prophylaxis treatment.

Trial sites (2)

Facility	City	Region	Status
The First Affiliated Hospital of Xiamen University	Xiamen	Fujian	Recruiting
Institute of haematology and Blood diseases hospital	Tianjin	Tianjin Municipality	Recruiting

More Institute of Hematology & Blood Diseases Hospital, China trials in China

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma Recruiting

Twice-per-weekSelinexor, 2 Days Melphalan Starting soon

A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma. Starting soon

Cohort of Nursing Homes Recruiting

Newly-diagnosed Pediatric Ph-positive B-ALL Protocol Recruiting

Other trials for the same condition

A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia Active, not recruiting

Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients Active, not recruiting

EPOCH-Economics and Patient Outcomes in China in Haemophilia Active, not recruiting

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B Recruiting

PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06992076 on ClinicalTrials.gov ↗ ← All trials in China